Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 5, pp 1383–1389 | Cite as

Safety and Effectiveness of Low-Dose Propofol Sedation During and After Esophagogastroduodenoscopy in Child A and B Cirrhotic Patients

  • Naoki Tanaka
  • Akira Horiuchi
  • Yoshiko Nakayama
  • Yoshihiko Katsuyama
  • Masatsugu Isobe
  • Toshifumi Aoyama
  • Eiji Tanaka
  • Shigeru Ohmori
Original Article

Abstract

Background

Effective and safe sedation for patients with liver cirrhosis is problematic.

Aim

To examine the safety and effectiveness of low-dose propofol sedation during and after esophagogastroduodenoscopy (EGD) in cirrhotic patients.

Methods

Study 1 was a prospective study in cirrhotic patients who underwent diagnostic EGD under propofol sedation. Propofol was given by bolus injection with an age-adjusted standard protocol consisting of 40 mg for patients <70 years, 30 mg for patients aged 70–89 years; additional injections of 20 mg propofol were given up to a maximum of 120 mg. The principal parameter was the occurrence of adverse events within 24 h after EGD. Secondary parameters included successful procedures, complications, and full recovery within 60 min. In Study 2, the residual effects of propofol were evaluated using a driving simulator and blood propofol concentrations in a subset of cirrhotic patients undergoing EGD and compared with healthy individuals. The principal parameter was driving ability.

Results

Study 1: Consecutive cirrhotic patients were entered and all 163 successfully completed EGD. The mean dose of propofol was 46 mg (range 30–120 mg). No complications occurred. Full recovery had occurred in 100 % 60 min after the procedure. No adverse events occurred within 24 h after EGD. Study 2: There were no significant differences in blood propofol levels between cirrhotic patients (n = 21) and healthy individuals (n = 20) after sedation. In cirrhotic patients, there was no deterioration in driving ability as compared with healthy individuals.

Conclusion

Low-dose propofol sedation provided safe and effective sedation for EGD in cirrhotic patients with rapid recovery.

Keywords

Esophagogastroduodenoscopy EGD Liver cirrhosis Propofol Sedation 

Abbreviation

EGD

Esophagogastroduodenoscopy

Notes

Acknowledgment

The authors thank David Y. Graham, MD, for his editorial advice.

Conflict of interest

None.

References

  1. 1.
    Assy N, Rosser BG, Grahame GR, et al. Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Gastrointest Endosc. 1999;49:690–694.PubMedCrossRefGoogle Scholar
  2. 2.
    McGuire BM. Safety of endoscopy in patients with end-stage liver disease. Gastrointest Endosc Clin N Am. 2001;11:111–130.PubMedGoogle Scholar
  3. 3.
    Vasudevan AE, Goh KL, Bulgiba AM, et al. Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy. Am J Gastroenterol. 2002;97:1717–1721.PubMedCrossRefGoogle Scholar
  4. 4.
    MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 1986;27:190–195.PubMedCrossRefGoogle Scholar
  5. 5.
    Lazzaroni M, Bianchi Porro G. Preparation, premedication, and surveillance. Endoscopy. 2005;37:101–109.PubMedCrossRefGoogle Scholar
  6. 6.
    Qureshi WA, Zuckerman MJ, Adler DG, et al. ASGE guideline: modifications in endoscopic practice for the elderly. Gastrointest Endosc. 2006;63:566–569.PubMedCrossRefGoogle Scholar
  7. 7.
    Koshy G, Nair S, Norkus EP, et al. Propofol versus midazolam and meperidine for conscious sedation in GI endoscopy. Am J Gastroenterol. 2000;95:1476–1479.PubMedCrossRefGoogle Scholar
  8. 8.
    Rex DK, Overley C, Kinser K, et al. Safety of propofol administered by registered nurses with gastroenterologist supervision in 2,000 endoscopic cases. Am J Gastroenterol. 2002;97:1159–1163.PubMedCrossRefGoogle Scholar
  9. 9.
    Vargo JJ, Zuccaro G Jr, Dumot JA, et al. Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial. Gastroenterology. 2002;123:8–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Horiuchi A, Nakayama Y, Katsuyama Y, et al. Safety and driving ability following low-dose propofol sedation. Digestion. 2008;78:190–194.PubMedCrossRefGoogle Scholar
  11. 11.
    Horiuchi A, Nakayama Y, Hidaka N, et al. Low-dose propofol sedation for diagnostic esophagogastroduodenoscopy: results in 10,662 adults. Am J Gastroenterol. 2009;104:1650–1655.PubMedCrossRefGoogle Scholar
  12. 12.
    Horiuchi A, Nakayama Y, Kajiyama M, et al. Safety and effectiveness of propofol sedation during and after outpatient colonoscopy. World J Gastroenterol. 2012;18:3420–3425.PubMedCrossRefGoogle Scholar
  13. 13.
    Horiuchi A, Nakayama Y, Fujii H, et al. Psychomotor recovery and blood propofol level in colonoscopy when using propofol sedation. Gastrointest Endosc. 2012;75:506–512.PubMedCrossRefGoogle Scholar
  14. 14.
    Horiuchi A, Nakayama Y, Tanaka N, et al. Propofol sedation for endoscopic procedures in patients 90 years of age and older. Digestion. 2008;78:20–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Tanaka N, Horiuchi A, Yamaura T, et al. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. J Gastroenterol. 2007;42:49–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Tanaka N, Horiuchi A, Yamaura T, et al. Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections. J Gastroenterol. 2009;44:577–582.PubMedCrossRefGoogle Scholar
  17. 17.
    Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413–418.PubMedCrossRefGoogle Scholar
  18. 18.
    Grant SA, Murdoch J, Millar K, et al. Blood propofol concentration and psychomotor effects on driving skills. Br J Anaesth. 2000;85:396–400.PubMedCrossRefGoogle Scholar
  19. 19.
    Cussonneau X, Smet ED, Lantsoght K, et al. A rapid and simple HPLC method for the analysis of propofol in biological fluids. J Pharma Biomed Anal. 2007;44:680–682.CrossRefGoogle Scholar
  20. 20.
    Byrne MF. Nurse-administered propofol sedation safety further confirmed—but can we really allow our patients to drive afterwards? Digestion. 2008;78:187–189.PubMedCrossRefGoogle Scholar
  21. 21.
    Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990;65:177–183.PubMedCrossRefGoogle Scholar
  22. 22.
    Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest Endosc Clin N Am. 2004;14:247–268.PubMedCrossRefGoogle Scholar
  23. 23.
    Khamaysi I, William N, Olga A, et al. Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study. J Hepatol. 2011;54:72–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Sharma P, Singh S, Sharma BC, et al. Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation. Endoscopy. 2011;43:400–405.PubMedCrossRefGoogle Scholar
  25. 25.
    Amorós A, Aparicio JR, Garmendia M, et al. Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy. Gastrointest Endosc. 2009;70:262–268.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Naoki Tanaka
    • 1
    • 2
  • Akira Horiuchi
    • 3
  • Yoshiko Nakayama
    • 3
  • Yoshihiko Katsuyama
    • 4
  • Masatsugu Isobe
    • 3
  • Toshifumi Aoyama
    • 1
  • Eiji Tanaka
    • 2
  • Shigeru Ohmori
    • 4
  1. 1.Department of Metabolic Regulation, Institute on Aging and AdaptationShinshu University Graduate School of MedicineShinshuJapan
  2. 2.Department of GastroenterologyShinshu University School of MedicineShinshuJapan
  3. 3.Digestive Disease CenterShowa Inan General HospitalKomaganeJapan
  4. 4.Division of PharmacyShinshu University HospitalShinshuJapan

Personalised recommendations